Algeria, Chad explore strengthening pharmaceutical industry

Algeria-Chad Pharmaceutical Cooperation

---

**HEADLINE:** Algeria-Chad Pharmaceutical Deal 2025: Regional Drug Manufacturing Strategy

**META_DESCRIPTION:** Algeria and Chad strengthen pharma ties to boost African drug production. What this means for investors in North and Central Africa.

---

## ARTICLE:

Algeria and Chad are deepening pharmaceutical sector cooperation, signaling a regional pivot toward local drug manufacturing and reducing dependence on imported medicines. This strategic alignment addresses a critical gap in West and Central African healthcare infrastructure—where 70% of pharmaceutical products are imported at premium costs, straining both public budgets and private healthcare systems.

### Why Pharmaceutical Cooperation Matters Now

The North and Central African pharmaceutical market faces compounded pressures. Healthcare spending across the Sahel and Maghreb is rising (averaging 4.2% annual growth), but local manufacturing capacity lags by decades. Algeria, holder of Africa's largest proven natural gas reserves, possesses industrial infrastructure and chemical feedstock advantages. Chad, positioned as a gateway to Central African trade corridors, offers geographic access to underserved markets across the Economic and Monetary Community of Central Africa (CEMAC).

The World Health Organization estimates that strengthening local pharmaceutical production across Africa could reduce medicine costs by 30-40% while creating 450,000+ manufacturing jobs by 2030. Algeria-Chad cooperation directly targets this opportunity.

### ## What Does Algeria Bring to the Partnership?

Algeria's pharmaceutical sector already manufactures 60% of domestic demand locally—the highest rate in the Maghreb. The country hosts 45+ licensed pharmaceutical factories, many operating excess capacity. Algeria's state-owned pharmaceutical company, SAIDAL, produces generics, antibiotics, and cardiovascular drugs at scale. Crucially, Algeria controls downstream chemical production (active pharmaceutical ingredients, or APIs), reducing raw material costs by 25-35% versus regional competitors. This vertical integration is the partnership's competitive edge.

### ## How Will Chad Benefit Operationally?

Chad's role centers on distribution, market access, and light-touch assembly operations. The country sits at the intersection of CEMAC, West African Economic and Monetary Union (WAEMU), and Sahel trade networks—positioning it as a pharmaceutical hub for 180+ million people across six countries. Rather than building factories (capital-intensive, 18-24 month timelines), Chad can establish quality-control and packaging centers for Algerian semi-finished products, creating jobs while shortening supply chains to final consumers. This model mirrors successful partnerships in East Africa (Kenya-Uganda pharma corridors).

### ## Market Implications for Investors

The Algeria-Chad pharmaceutical initiative carries three investor signals:

**1. Regional Consolidation:** Expect M&A in smaller Sahelian pharmacies and distributors as Algerian firms acquire market share across CEMAC.

**2. API Localization:** Investors in chemical manufacturing should monitor API production capacity expansions in Algeria—margins are 2-3x higher than finished goods.

**3. Regulatory Harmonization:** Both countries are moving toward African Medicines Agency (AMA) standards, creating compliance cost advantages for early movers.

The broader context: Africa's pharma market hit $41.3 billion in 2023 and is projected to reach $65 billion by 2030 (CAGR 6.8%). Yet local manufacturing accounts for only 18% of supply—predominantly in South Africa, Egypt, and Nigeria. Algeria-Chad is positioning itself to capture the underserved Sahel-Maghreb slice of that growth.

---

##